Cyril J. Peter
- ASSISTANT PROFESSOR Psychiatry
- Dr. Peter is an Assistant Professor of Research in the Division of Psychiatric Epigenomics. For two years, Dr. Peter has been an integral part of Schahram Akbarian’s, MD, PhD, laboratory team, which recently came to Mount Sinai and is studying the epigenetic mechanisms of psychiatric disorders.
Dr. Peter’s research focuses on identifying and characterizing novel proteins and molecular interactions involved in chromatin remodeling and epigenetic regulation in human vertebrae and brain. His goal is to translate those findings and develop new chromatin modifying drugs that have therapeutic potential for neuropsychiatric diseases. In addition, he will contribute to grants and projects for the Center of Excellence, organize a monthly seminar on psychiatric epigenetics, and serve as a mentor to graduate and postdoctoral students.
Prior to joining Mount Sinai, Dr. Peter was an instructor at Brudnick Neuropsychiatric Research Institute at the University of Massachusetts Medical School. During his training, he identified a novel chromatin protein complex, which may play a key role in epigenetic mechanisms in the brain.
Shulha HP, Crisci JL, Reshetov D, Tushir JS, Cheung I, Bharadwaj R, Chou HJ, Houston IB, Peter CJ, Mitchell AC, Yao WD, Myers RH, Chen JF, Preuss TM, Rogaev EI, Jensen JD, Weng Z, Akbarian S. Human-specific histone methylation signatures at transcription start sites in prefrontal neurons. PLoS biology 2012; 10(11).
Peter CJ, Akbarian S. Balancing histone methylation activities in psychiatric disorders. Trends in molecular medicine 2011 Jul; 17(7).
Houston I, Peter CJ, Mitchell A, Straubhaar J, Rogaev E, Akbarian S. Epigenetics in the human brain. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 2013 Jan; 38(1).
Peter CJ, Evans M, Thayanithy V, Taniguchi-Ishigaki N, Bach I, Kolpak A, Bassell GJ, Rossoll W, Lorson CL, Bao ZZ, Androphy EJ. The COPI vesicle complex binds and moves with survival motor neuron within axons. Human molecular genetics 2011 May; 20(9).
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Dr. Peter did not report having any of the following types of financial relationships with industry during 2012 and/or 2013: consulting, scientific advisory board, industry-sponsored lectures, service on Board of Directors, participation on industry-sponsored committees, equity ownership valued at greater than 5% of a publicly traded company or any value in a privately held company. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website at http://icahn.mssm.edu/about-us/services-and-resources/faculty-resources/handbooks-and-policies/faculty-handbook. Patients may wish to ask their physician about the activities they perform for companies.
Hess Center for Science and Medicine Floor 9 Room 202
1470 Madison Avenue
New York, NY 10029